Randomized controlled clinical study of Yiqing oral liquid and paxlovid in the treatment of novel coronavirus infection

INTERVENTION: experimental group:Paxlovid+Yiqing Oral Liquid;control group:Paxlovid+ Yiqing Oral Liquid Placebo; CONDITION: Novel Coronavirus Pneumonia (COVID‐19) PRIMARY OUTCOME: The standard rate of N gene and ORF gene Ct value in the detection of new coronavirus nucleic acid;7‐day clinical symptom score; SECONDARY OUTCOME: Time for the first nucleic acid to turn negative;Disease exacerbation rate; INCLUSION CRITERIA: 1. The Ct value of both N gene and ORF gene in the nucleic acid detection of novel coronavirus infection is less than 30 (fluorescence quantitative PCR method, the limit value is 40); 2. Aged 18‐85 years; 3. The clinical classification belongs to mild, common and severe; 4. More than 1 high‐risk factor for progression to severe/critical illness; 5. Voluntarily sign the written informed consent.